Molecular Partners Ag (MOLN) Other Operating Expenses (2024 - 2025)
Molecular Partners Ag (MOLN) posted quarterly Other Operating Expenses of -$116.3 million for Q4 2025, down 479.19% year-over-year from $30.7 million in Q4 2024, and down 9301382358.91% quarter-over-quarter from $1.25 in Q3 2025.
Molecular Partners Ag (MOLN) Other Operating Expenses (2024 - 2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Other Operating Expenses for 2 consecutive years, with -$116.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Operating Expenses fell 479.19% year-over-year to -$116.3 million; the TTM figure through Mar 2026 stood at -$116.3 million (down 479.19% YoY), while the FY2025 annual figure was -$116.3 million, down 479.19% from the prior year.
- Other Operating Expenses slipped to -$116.3 million in Q4 2025 per MOLN's latest filing, from $1.25 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.25 in Q3 2025 and bottomed at -$116.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Molecular Partners Ag | 157.66 Mn | 157.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -116.28 Mn |
| Sep 30, 2025 | 1.25 |
| Dec 31, 2024 | -20.08 Mn |